Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Oscar Health (OSCR) has been back on investors’ radar after a sharp stock rally following its business update at the Goldman Sachs Healthcare Conference, where management reaffirmed full-year 2026 guidance and highlighted favorable utilization trends.

See our latest analysis for Oscar Health.

The stock’s rally around the Goldman Sachs Healthcare Conference and upbeat commentary on utilization trends come on top of very strong momentum, with a 90 day share price return of 118.52% and a 1 year total shareholder return of 101.60% from a last close of $28.91.

If the renewed focus on healthcare technology has your attention, it could be a good moment to see what else is moving across 40 healthcare AI stocks.

With Oscar Health now trading near its highs and recent returns far outpacing the broader insurance sector, the key question is whether investors are overpaying for momentum or if the stock still reflects an underappreciated growth story.

Most Popular Narrative: 88% Overvalued

At a last close of $28.91 versus a narrative fair value of $15.40, the most followed view points to a stock price running well ahead of its modeled worth. That gap rests on a detailed set of growth and profitability assumptions.

Analysts expect earnings to reach $649.6 million (and earnings per share of $1.91) by about April 2029, up from $443.2 million of losses today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $951.9 million in earnings, and the most bearish expecting $476.5 million.

Read the complete narrative.

Curious what kind of revenue run rate, margin reset and earnings profile those figures assume, and how they back into that future profit multiple and fair value path.

Result: Fair Value of $15.40 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the narrative could still be challenged if digital adoption and AI driven efficiencies cut costs faster than expected, or if repricing restores margins more quickly.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: What The P/S Ratio Is Saying

The narrative fair value of $15.40 suggests Oscar Health is overvalued, but the current P/S ratio tells a different story. At about 0.7x sales, the stock sits below the US Insurance industry at 1.1x and below peers at 1.2x, and it also lines up with a fair ratio of 0.7x. That mix of premium share price and discounted sales multiple leaves you weighing which signal matters more for risk and potential upside.

Story Continues

To see how those numbers stack up across peers and the industry, See what the numbers say about this price — find out in our valuation breakdown.NYSE:OSCR P/S Ratio as at Jun 2026

Next Steps

If the mixed signals on valuation and growth are leaving you on the fence, now is a good time to review the full picture yourself and weigh both sides of the story. You can start with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If this story has sharpened your thinking, do not stop here. The wider market is full of opportunities that could fit your goals even better.

Spot potential mispricing early by scanning 46 high quality undervalued stocks, which combine solid fundamentals with price tags that may not fully reflect their financial profile. Prioritise strength and staying power by focusing on companies in the solid balance sheet and fundamentals stocks screener (47 results) so you are not relying on fragile capital structures. Get ahead of the crowd by checking the screener containing 20 high quality undiscovered gems before attention and liquidity shift elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include OSCR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

In this episode of Motley Fool Hidden Gems Investing, Motley Fool contributors Tyler Crowe, Matt Frankel, and Lou Whiteman discuss:

Broadcom’s good earnings.Playing the expectations game in a volatile market.Stocks doing well in downtrodden industries.Listener questions: How will the SpaceX, Anthropic, and OpenAI IPOs impact cash on the sidelines and ETFs?

To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. When you're ready to invest, check out this top 10 list of stocks to buy.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

A full transcript is below.

Should you buy stock in Broadcom right now?

Before you buy stock in Broadcom, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Broadcom wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $442,220! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,230,114!

Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of June 11, 2026.

This podcast was recorded on June 4, 2026.

Tyler Crowe: We've got Broadcom stock whiplash today on Motley Fool Hidden Gems Investing. Welcome to Motley Fool Hidden Gems Investing. I'm your host, Tyler Crowe, and today I'm joined by longtime Fool contributors Lou Whiteman and Matt Frankel. Today, we were going to mix it up a little bit. We thought we're going to do a bunch of different segments and do some basically non-earnings takes because it's June. We don't normally get a lot of surprise earnings stuff, but then Broadcom had to go and give its earnings, and now its stock’s down, I think, almost 15% as we are taping today, as we're going to get into. I'll let you guys really digest the numbers here. But by all objective metrics, all the numbers looked good. The guidance looked fine. Is this really just expectations game, Lou?

Lou Whiteman: I think it is. Expectations are everything. It's glass half full of glass empty. Stock is up 15%, just heading into earnings. When you get that sort of expectations, any slight hiccup, any slight sneeze can set you back. This was a slight miss on revenue, but look, it's brutal when people are expecting enough. Apparently, it was enough to outweigh 140% gains in AI semiconductor sales, which I don't know, Tyler, sounds pretty OK to me.

Tyler Crowe: Matt, you were the task a little bit more with the nitty-gritty of the numbers here. What did you see in this that was like, maybe not great. I don't know. It's hard to look at these and say, Yeah, we should definitely be dropping the stock by 15% because that's just what we do these days.

Matt Frankel: It's not only Broadcom. CrowdStrike also reported. We're getting all the reports from companies that use weird fiscal years, and some of them haven't been too impressive. But there was a lot to like here, 48% revenue growth, they beat on the bottom line. As Lou said, 140% roughly growth in AI semiconductor revenue. Guidance was strong, but if you look into the guidance, the AI revenue that they're guiding for is not quite what the market expected, so that could be driving a little bit of the sell-off. Any slowdown in AI or perceived slowdown is enough to scare investors, and it's not just that it was running up 15% heading into earnings, Broadcom was up 90% over the past year. In a nutshell, this stock went into the report priced for a blowout quarter and blowout guidance. It was a good quarter. I wouldn't call this a blowout quarter, especially on the AI side of the business, not a blowout.

Tyler Crowe: We certainly did see a lot of blowouts this most recent quarter looking at a lot of these suppliers. Taiwan Semi, basically everyone was like, everything is awesome. With Broadcom's numbers looking pretty good. It was almost like comparing to everyone else. Is like, Well, they were that good. Can you do as well? This touches on a couple of top themes and topics we've discussed so far during this week. When the three of us were on the show on Tuesday, we were talking about how much does narrative play into your thesis? Narrative is also valuation-based. We were talking about this with Dollar General because, as a value play as a stock, you are betting on a return to median, return to average valuation.

Right now, we're all the narrative is defying expectations to justify very high valuations. At the same time, too, it touches on this idea of the start-stop whack-a-mole discussion about the AI build-out that, Lou, you, I, and Travis were talking about yesterday, where it seems like every couple of months here, we're talking about the next bottleneck. At first, it was is going to be chits. Then it became memory chips. Now we're talking about, the old companies like Dell that are just building off products, and we can name like 15 other suppliers where somewhere there's a stop-start going on here where somebody's doing awesome, but then, just because they didn't blow out earnings, they're going to have a 15% stock drop.

Lou Whiteman: Two points here, one macro, one micro, I guess. First of all, the macro, the narrative. I think you are so right and I think investors better be watching the narrative right now because there is a real indication that nothing is good enough. I look at what happened with Nvidia’s quarter. Look what the stock did there. Expectations are so out of this world right now that I don't know if any company, almost, can satisfy the market long term. For strong companies that can outlast the cycle, that's just an annoyance. But if you are in some of the, I guess, more speculative AI companies, I think this should be a warning sign to you that nothing is good enough, so look out below.

Specific to Broadcom, look, there are massive expectations still up ahead. CEO Hock Tan is forecasting $100 billion in annual AI chip revenue in fiscal ‘27. They're on pace to do about half of that this year, Tyler, and it took triple-digit gains to get to that 50 billion that they hope to do this year. I see that the stop-start nature of this, the questions about potential fragility, and it scares me. You add in the fact that OpenAI and Anthropic are going to account for a lot of that growth. Those are two very different companies right now. Even if OpenAI gets their act together and does well, you are putting a lot of eggs in just a couple of baskets with that customer concentration. I'm not predicting gloom. Broadcom is a good company, but right now, it's just hard to look at this and say, yes, everything's fine, everything goes up from here.

One other thing, software revenue, which is supposed to be recurring, to balance this out. That only grew by 9%. All of this growth is going to have to come based on their ability to keep selling hardware at really amazing levels. We'll see how long that lasts.

Matt Frankel: To Lou’s point, the expectations are huge here. You mentioned they're predicting about $100 billion of AI revenue in 2027. For about $40 billion of that, a little more is expected to come from Anthropic alone. OpenAI is a big client. The anthropic and OpenAI IPOs are really worth paying attention to. Anthropic just raised $65 billion. We've talked about this with other companies. I think Oracle was one of them where these commitments they're going to need to pay. They raised $65 billion. OpenAI raised $120 billion recently. That's not going to be enough for all of their commitments. These IPOs really need to go well, they need to get strong valuations. OpenAI and anthropic IPOs are probably the single most important near-term story for Broadcom investors to watch. The 2027 and 2028 growth story for the company, which the IPOs are going to directly support. It's largely intact for now, but that could change if demand cools off.

Tyler Crowe: We'll be getting into that in a later segment, but the amount of money that needs to be raised this year to make those commitments to Broadcom and all their other suppliers is looking pretty hefty and could have some pretty profound impacts on the market in general, beyond just those individual companies. But we're going to hit that after the break. But before that, we're going to actually take a pause from the AI discussion and just kind of look at some other sectors and some stocks that are really changing up the narrative of the sector that they're in. We'll hit that after the break.

[ADVERTISEMENT]

Tyler Crowe: I was reading an investing newsletter a couple of days ago, and there was a quote from the chief economist at Apollo talking about diversification and the importance of it. This was an interesting quote to me. It was factor investing tells investors not to be overexposed to just one factor. What he said was, the new 60/40 is now the AI versus non-AI thing. For those who aren't familiar, 60/40 was the benchmark gold standard for individual investors, people, probably not picking individual stocks. 60% of your money in stocks, 40% of your money in bonds, maybe you start changing that as you get older, but it was the standard benchmark that most wealth advisors told you to do to get diversification in the market.

As this quote is saying, it's not just the factor of bonds versus stocks, but it's also how much diversification do you have away from AI? In the spirit of that, we wanted to dedicate a whole segment to basically sectors and parts of the market that just aren't AI. Specifically, we've had a pretty bifurcated market so far. We've had some industries doing extremely well and others have been taking a bit on the chin. I think insurance, healthcare, biotech has done surprisingly not well. Well, energy, semiconductors, technologies absolutely fly. In that vein, what we played a little game with these guys. I each wanted you guys to pick one stock from an industry and find a stock that you find that is bucking the sector trend. Is there a company that's doing lousy in these awesome sectors or a company that's doing gangbusters in a downtrodden sector? I want to start with you, Matt. What's the sector in the stock that you're like, This is interesting.

Matt Frankel: Well, it's been a long time since I've gotten to talk about real estate because all we talk about is AI and SpaceX lately. I'm going to bring up.

Tyler Crowe: That's the whole point of this segment.

Matt Frankel: I'm going to bring up a real estate stock. Over the past three months, the S&P 500 as a whole has gained about 11%, mostly because of the mega‑cap tech stocks. Meanwhile, the real estate sector has been almost exactly flat. It was up 0.02% as I was looking this morning. There are some good reasons for it to be fair, specifically the fact that inflation is at its highest level in three years. There are legitimate concerns about the Fed raising rates. Real estate is a very rate-sensitive sector as a whole.

One that has really bucked the trend is Ryman Hospitality Properties. Ticker is RHP. It's up 18% in the past three months, even beating the S&P, not just the real estate sector. Hotel real estate is generally less rate-sensitive than other real estate subsectors. Unlike things like warehouses and retail properties which rely on long-term leases have predictable cash flow, hotels rent their space by the night and share prices; therefore are more governed by the business performance, which can really ebb and flow over time. Ryman's business has been impressive. In the first quarter, revenue and net income were at all-time highs for that time of year. The company raised its full-year guidance. Average daily rates for the hotel rooms and out-of-room spending were both up by double digits year over year. Their entertainment division is performing really well, especially that Old Red dining and entertainment brand just announced its seventh location. Its flagship Vegas location is dramatically outperforming expectations. Adjusted FFO, funds from operations, which is the real estate version of earnings, grew by 19% year over year. That's a rapid pace for real estate.

Tyler Crowe: Permit me a little bit of a follow up question here. When I think hospitality, too, though, I do think sensitivity to macroeconomic factors. When you look at Ryman, because it is a hospitality REIT, is this a specific REIT that has some call it macroeconomic macro vibes resiliency in it with its business model, or is it a little bit of ride the wave until it's no longer working?

Matt Frankel: That's a really good question because they're a group-focused hotel. The reason that that's important is that they focus on conferences, conventions, things like that, and these tend to book three,, four years in advance. They have a lot of future revenue visibility as opposed to an operator of a Hilton or a non-group focused hotel. They have some resilience, and you got to think of what they're being compared to in year over year. International travel was way down a year ago. That's coming back a little bit. Group events are a very resilient part of the hotel market. You bring up a really good point. I wouldn't really want to invest in a leisure hotel operator with macro uncertainty, but one that has that group-focused business, which is more than half of Ryman's business, it does have a little more visibility.

Tyler Crowe: Lou, I think we're not going to do anything real estate related to what you're looking at here.

Lou Whiteman: No, I will say, though, I'd rather own Ryman than stay at the Grand Old Opery. There's that for it. Look, I'm looking at the transports. I'm going to apply my gratists too, but it's been a pretty crummy few years for the transports. There were a lot of factors driving that. We were coming down from the sugar high of the pandemic where everything was shipped. ASAP. We've had the added uncertainty of tariffs, trade wars, and macro concerns, slowing economy. Big customers tend not to stock up on inventories if they're worried, the economy is slowing. It all has added up to underperformance, really crummy numbers. Nasdaq Transportation index has underperformed the market by 25 percentage points over the last three years.

In that environment, XPO, a trucking company, is up 340%. Easily beating both the transports and the broader market. Now some of that is good fortune. A big competitor, yellow, liquidated, XPO picked up a lot or a good bit of that business at literally prices that made it EB a positive just from Day 1. But it's also management deserves a lot of credit here. This is a story of simplification. Split out a couple of other units to just focus on one thing and being good at one thing. They shedded unrelated businesses that are fine on their own, but not part of the story. They also hired a ton of really, good people from competitors that quite frankly were doing better than them and they've started to shift their focus to margin over volume. This is, I think, sustainable. We've seen with Old Dominion, how a good operator over time can just outperform the sector and the market just based on the strength of their operations. I think XPO has elevated itself to that level.

Tyler Crowe: Similar follow up, and this is a discussion you and I, I think we had a couple of years ago too, where it felt like a time where trucking, especially was like, you've got Old Dominion XPO is up and coming, but you had a lot of subpar operators in this industry, so it was Old Dominion and to a lesser degree, XPO was taking candy from a baby taking market share here because they couldn't seem to get their hand out of the paste jar. It seems like that's less the case now. Obviously, Old Dominion XPO are dominant players here, but some of the other players in the industry found religion, I guess, you will, on March and on capacity additions at a reasonable rate. With that in mind, with the outperformers like XPO and Old Dominion that have done so well, now that they're facing more competent competition, is the growth opportunities as robust here or is it a little bit more of a knife fight for share?

Lou Whiteman A couple of things going on, I think. For one, until recently, XPO didn't deserve to be in that conversation as a good performer. What you've seen is them enter this. I think it's more of a risk for, say, an Old Dominion, which has benefited over the years for just being the only ones who could get pricing right. The other answer is scale. At the end of the day, you still have advantages to scale that you can be more efficient, even if it's the super friends, a couple of players that are really, better than anyone else, there's enough business out there. XPO is finally trading. At a multiple similar to Old Dominion, which you never saw a few years ago. I do think probably the 340% over three years, that we can't repeat that, that a lot of that was playing catch-up. But I think that, like I said, Old Dominion is the model. I think there is room for a few companies here that just outperform their peers and, over time, outperform the market.

Tyler Crowe: Trucking, as boring as it sounds, it's been a weirdly fascinating industry over the past I don't know, at least decade to follow. Interesting to see XPO, I can almost say getting down to fighting weight, I guess would be the best way to put it so they can compete. I'll give my answer here too, because one industry that's been quite lousy this year and so far, year to date, as well as over the past year or so has been insurance. Obviously there is reasons for that. Insurance is a cyclical industry, and a lot of the underperformers in the insurance industry in general have been a lot of high flyers, especially your specialty insurers and things like that. You're also seeing a lot of pricing pressure on the big lines of insurance that we see automotive and homeowners, some of the biggest a lot of these competitors are trying to take share and when you take share, profitability sinks and that tends to hurt stocks.

But health insurance in particular has been hit even harder. Rising costs are getting hard to control, plus lots of backlash from patients, and just in general, the feeling towards health insurers has been not great because high rates of denials, higher copays. It's the stuff that frustrate people using their health insurance. It's led to quite a bit of unpopularity. This is where there’s this one company that seems to be separating itself from the rest here, and obviously, it’s a small one, so it has that opportunity. It's called Oscar Health, ticker OSCR. They straddle this health insurance technology and health insurance broker business. Most of what it did was, when it got started in 2012, it was contingent on the American Healthcare Act or the Obamacare marketplaces. What it did was it set up programs where small business owners would let their employers buy individual insurance and using Oscar's platform, the employer would basically reimburse the individual for it, and that would allow them to meet their compliance for insuring their customers, while giving them — their employees, excuse me,— while giving them more options and actually was a way of relatively controlling costs because there were some subsidies related to using the marketplaces.

It kinda worked for a while, but when the marketplaces, ObamaCare marketplaces are doing well. But many insurers have left that program, and it’s been walking in the woods, trying to figure out what it wants to do next, and figure this out, and it’s starting to gain traction here. It's now more focused on providing individual insurance themselves, taking more of the underwriting burden, and so far, they've done a decent job. Their combined ratios are, have been varying. I think their health loss ratios were 70% in the most recent quarter, combined ratios 87, 88, which by insurance standards, is quite good. Any insurance, almost any line that you're looking at, below a 90% coverage loss ratio, which is basically how much you have to pay out in costs for healthcare or auto claims or anything like that, relative to the premium bring in. It's basically saying you have a 10% operating margin. Industry lingo. I know it's silly, but it works pretty well for an insurer.

Despite the fact that they've been winding down some big-name programs, they had a program with Cigna that didn't quite work out. They've been focusing more on the individuals. It seems to be working. I'm not saying they're out of the woods yet, and I'm not wholeheartedly going to pound the table to say, this is an awesome company now, but it's very interesting to see and obviously the stock is reflecting the fact that they are getting some traction with what they're doing. Coming up next, we're going to get into listener questions about all these massive IPOs coming to market.

Hey, just a reminder, we love answering your questions. If you do want your question answered on air, go ahead and email us at podcasts @fool.com. Three rules as always. No. 1, keep it Foolish, two keep it short enough for us to read, and three, we cannot give personalized advice, so let's try to keep it relatively generic.

As long as we've been taking questions, what we have seen more than anything else so far is questions about SpaceX, Anthropic and OpenAI IPOs, specifically to how they're going to impact the broader market. We're talking about early index inclusion for a lot of these companies because they're going in so big, and the questions have been numerous. But there's just two that are most representative of what we're talking about. This was from Ben Jackson. "With the recent changes to the Nasdaq index and immature over to value companies like SpaceX IPO with little supply — he's being a little diminutive here — but should your average ETF investor or index investor be reconsidering or selling their ETF portfolio to avoid the long-term turbulence that these large IPOs going into these ETFs may cause. This one is from Thomas Bianco. If we already know that approximately $4 trillion of new money will be sucked up in these three IPOs, basically, the combined market value, they think is going to be around $4 trillion for all three of them when they go public, How can we adjust our current equities positions to account for these forthcoming disruptions?

Now, I want to just give a little bit of context here because all the money we're going to be sucking up with these large ones. Right now, data from the Federal Reserve of St. Louis says that about $8.1 trillion is in money market funds as of fourth quarter of 2025. That sounds like a lot, but you also have to factor, how much is in the market in general. We have a thing at The Motley Fool. It’s called the PT potential growth indicator. Basically, it takes all the cash that's on the sidelines or in money market accounts, like the Fred data says and then divided by the total stock market valuation, which is at about 10.1%. Over the past 30 years, that is a little bit on the lower side. You could say that that's saying, everyone's pretty optimistic. They want to be in the market relative to what we see in other different times. With those little factoids, the amount of money that we're talking about here, guys, what do you have to say to Ben and Thomas' questions here?

Lou Whiteman: I think the first thing we should note is that the IPO headline number isn't the same as the money raised. SpaceX is looking for a $1.8 trillion IPO valuation, but it's only actually raising 75 billion. That said, 75 billion is a massive number for an IPO. I think the point is still relevant. The net impact, though, I'm not sure what I think. It might suck money away from other areas because again, we have a lot of demand here. $75 billion worth of money has to be found here. But over the next six months, billions of dollars in SpaceX stock is going to be unlocked and free to trade. These are people who got in before the IPO. If those insiders decide to sell, that could free up at least 75 billion, if not more for other opportunities that could impact other stocks in a positive way. That actually could be a positive impact in some ways, Tyler. Bottom line, though, is the only thing we know for certain is it's going to cause volatility. I personally am not going to reposition things or do anything in anticipation of this. I think that, yes, there could be volatility, but over time, I think this will balance itself out as a long term focused investor. I'm not going to lose sleep on this, I'm going to just make some popcorn and watch.

Matt Frankel: As Lou said, the money raised won't be in the trillions of dollars, but the latest forecast is for around 240 billion across those big three, SpaceX, Anthropic, and OpenAI. Just to put that in context, in 2025, the entire IPO market, all companies raised about $45 billion combined. The largest U.S. IPO previously raised about 22 billion. We are in uncharted territory. There’s plenty of money on the sidelines, as Tyler mentioned, the money market accounts, but the reality is that a lot of money flowing into these three IPOs is going to have to come from somewhere, and existing stock investments are probably going to be a big source. Specifically, I would think that most people are going to sell Magnificent 7 shares to invest in some of these. No one's going to sell their realty income stock to buy SpaceX is my point there. Tesla could be an interesting one to watch. A lot of Elon Musk fans could sell one Elon Musk stock to buy another.

But on the other hand, there is a case to be made that there's going to be a lot of new money flowing into the market this year, not just because of these IPOs. These IPOs are certainly increasing the overall interest in the stock market by retail investors. As we're recording this, I actually got a notification from my broker that the SpaceX IPO is available. A lot of people are taking notice. It's going to be an interesting year for sure. All three could create significant short-term volatility, but like Lou said, I'm not losing sleep over it. I think it's going to work itself out in the long term, and I'm not planning on buying any of these three on Day 1, at least.

Tyler Crowe: Feel like we're probably all going to get that SpaceX email from our brokers in the next week or so I want to just actually conclude with this, too, about ETFs and allocations and things like that. This is an important thing for people to consider when they're buying ETFs. Say you're buying a broad-based S&P 500 ETF, there are two different types. There are market cap-weighted ones, which is obviously the ones that are going to be most influenced here by the large amount of money going into them. But there's also equal-weight CAP or equal-weighted indices as well, where instead of doing market cap as, it's every single company at every equal weights. It's pretty self-explanatory. Ones like this are obviously going to probably see less volatility relative to these trades. If you are looking to get broad exposure to an entire market, but are perhaps more skittish, I guess you could say, of these mega-cap companies coming in and becoming a larger and larger portion of what's supposed to be a broad-based index. There are equal-weight index options out there that might be worth considering.

As always, people on the program may have interest in the stocks they talk about, and The Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear. All personal finance content follows Motley Fool editorial standards and is not approved by advertisers. Advertisements are sponsored content and provided for informational purposes only. To see our full advertising disclosure, please check out our show. Thanks to producer Dan Boyd and the rest of the team for Lou, Matt, myself, thanks for listening, and we'll chat again soon.

Lou Whiteman has positions in Taiwan Semiconductor Manufacturing and XPO. Matt Frankel, CFP® has no position in any of the stocks mentioned. Tyler Crowe has positions in Ryman Hospitality Properties. The Motley Fool has positions in and recommends Broadcom, CrowdStrike, Nvidia, Old Dominion Freight Line, Taiwan Semiconductor Manufacturing, and Tesla. The Motley Fool recommends Ryman Hospitality Properties and XPO. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Check out some of the companies making the biggest moves midday: Trucking companies — Freight stocks sold off in reaction to Amazon saying it will open its less-than-truckload shipping services to companies outside its own network, posing a threat to industry incumbents. FedEx Freight Holding and Old Dominion Freight Line both slumped 5%; XPO dropped 4%; and Saia and ArcBest each fell 3%. Amazon itself dipped 2%. Super Micro Computer — The AI server maker plunged 18% after setting plans to raise $7 billion through the sale of equity- and equity-linked securities to help cover the cost of hardware component purchases. Chip stocks — Semiconductor companies continued their recent decline, with Micron Technology dropping 4%, Advanced Micro Devices falling almost 5% and Broadcom shedding 5%. Devon Energy — The oil and gas explorer rallied more than 6% after Evercore ISI raised Devon to outperform after what it called the company's "better-than-expected mid-month update." Devon management on Tuesday updated investors on its outlook following the purchase of Coterra Energy in early May for about $58 billion. Cracker Barrel — The Southern country-themed restaurant chain soared 24% after raising its full-year revenue and adjusted EBITDA guidance. Cracker Barrel also reported fiscal third-quarter earnings of 29 cents per share on $797.4 million in revenue, topping expectations. Analysts polled by FactSet had expected a loss of 48 cents per share and revenue of $776.7 million. Casey's General Stores — The convenience store and gas station chain surged 14%. Casey's posted better-than-expected fiscal fourth-quarter results, FactSet said, helped by rising fuel margins and prepared food and dispensed beverage sales ahead of last year. Fiscal 2027 EBITDA was forecast to grow 8%-10%. Gambling stocks — DraftKings climbed 5%, Rush Street Interactive rose more than 4%, Flutter Entertainment and SGHC Ltd. added 3% and Penn Entertainment advanced nearly 3%. DraftKings management told a Jefferies investor conference that it's confident of no material revenue cannibalization from prediction markets, and anticipated the World Cup will drive engagement and prediction volume in the second half, FactSet said. Robinhood Markets — The financial services trading platform jumped 5% after saying late Tuesday that total platform assets rose 9% in May compared with April, and 48% from the year-earlier period. CEO Vlad Tenev wrote in a social media post that Robinhood received regulatory approval to serve as an underwriter of initial public offerings. Oscar Health — The New York-based health insurer added 3% after Barclays upgraded Oscar to overweight Wednesday, saying it "offers the most direct leverage to a potential multi-year re-rating, alongside a margin recovery cycle as repricing actions take hold." Cava — The fast-casual restaurant chain was upgraded at UBS to buy from hold on its "compelling growth story." The stock climbed 6%. BILL Holdings — The cloud-based software provider dropped 4% to a 52-week low. Truist downgraded BILL to hold and slashed its 12-month price target to $38 from $45 previously. Gold miners — Gold miners fell alongside futures contracts for delivery of gold in August, which dropped 2%. Anglogold Ashanti tumbled nearly 6%, while Harmony Gold Mining fell more than 2% and Gold Fields lost more than 4%. Hecla Mining shed 2% and NovaGold Resources lost 3%. — CNBC's Michelle Fox, Lisa Kailai Han and Jordan Novet contributed reporting

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Oscar Health nutzt seine proprietäre Technologieplattform, um den US-amerikanischen Individualgesundheitsversicherungsmarkt zu stören. UnitedHealth Group bietet eine unübertroffene Skala und diversifizierte Einnahmequellen durch seine Optum- und UnitedHealthcare-Segmente an. Welches Gesundheitsunternehmen ist das bessere Kaufangebot für 2026?

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Zusammenfassung (600 Wörter)

Am Ende der Gewinnperioden für Krankenversicherungsunternehmen präsentierte sich das Bild gemischt, wobei erhebliche Kursrückgänge in der gesamten Branche auftraten. Obwohl die Gesamtumsätze der Gruppe um einen bescheidenen 0,8 % gegenüber den Analystenschätzungen übertroffen wurden, variierten die Ergebnisse der einzelnen Unternehmen erheblich, was zu kumulierten Kursstürzen führte.

Die grundlegenden Herausforderungen, denen die Krankenversicherungsbranche gegenübersteht, sind gleichbleibend: Rentabilität hängt von einer genauen Risikobewertung und Kostenkontrolle sowie dem Umgang mit regulatorischen Änderungen und wirtschaftlicher Volatilität ab. Demografische Veränderungen – eine alternde Bevölkerung – zusammen mit der steigenden Nachfrage nach personalisierter Gesundheitsversorgung und Fortschritten in der Datenanalyse stellen Wachstumschancen dar. Die Gegenkräfte umfassen jedoch weiterhin regulatorische Bedenken hinsichtlich der Preisgestaltung, das Potenzial für staatlich geförderte Gesundheitsreformen (wie erweiterte öffentliche Optionen) und anhaltende Inflation in der Gesundheitsversorgung, die alle zu einer Schwankung der Gewinnmargen beitragen.

Die Debatte über Künstliche Intelligenz (KI) ist zentral für die Bedenken der Anleger. Während KI potenzielle Vorteile in Bereichen wie Unterversicherung, Betrugserkennung und Schadenabwicklung bietet, sind ethische Bedenken – einschließlich des Risikos, bestehende Vorurteile zu verstärken und gesundheitliche Ungleichheiten zu verschärfen – ebenfalls erheblich.

Unternehmensleistungen:

• UnitedHealth (UNH): Trotz der Berichterstattung über 113,2 Milliarden US-Dollar (um 12,3 % im Jahresvergleich) fiel UnitedHealths Aktien um 22,3 % seit dem Bericht aufgrund einer enttäuschenden Gewinnprognose für das Gesamtjahr.
• Clover Health (CLOV): Clover Health glänzte mit einer Umsatzsteigerung von 44,7 %, übertraf die Analystenschätzungen deutlich. Der Aktienkurs sank jedoch um 21,2 % seit dem Bericht, was die Enttäuschung der Anleger widerspiegelt, trotz der starken Ergebnisse.
• Molina Healthcare (MOH): Molinas Umsatzsteigerung von 8,3 % enttäuschte die Erwartungen und führte zu einem Kursrückgang von 24 %.
• Centene (CNC): Centenes Umsatzwachstum von 21,9 %, obwohl es die Erwartungen übertraf, wurde durch einen deutlichen Kundenverlust und eine enttäuschende Gewinnprognose für das Gesamtjahr gemildert, was zu einem Rückgang der Aktie um 14,2 % führte.
• Oscar Health (OSCR): Oscars Umsatzwachstum lag deutlich unter den Erwartungen der Analysten, und seine starke Gewinnprognose für das Gesamtjahr, kombiniert mit einem Umsatzmangel, führte zu einem Rückgang des Aktienkurses um 7,2 %.

Marktkontext und sich ändernde Bedenken:

Der Gewinnbericht ereignete sich inmitten allgemeiner Marktängste, insbesondere hinsichtlich der potenziellen Auswirkungen von KI auf verschiedene Sektoren, darunter Software und Kryptowährungen. Eine Verschiebung des Anlegerinteresses erfolgte hin zu sichereren Vermögenswerten, als die Befürchtungen hinsichtlich technologischer Störungen zunahmen. Das Konfliktgeschehen zwischen den USA und dem Iran lenkte jedoch schnell die Aufmerksamkeit des Marktes ab und führte zu einer Veränderung der Anlegerstimmung und einer Rotation weg von Technologie hin zu traditionelleren sicheren Häfen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Okay, here's a 500-word summary of the text, followed by a German translation:

Summary (500 words)

This article from StockStory analyzes three stocks – Marriott (MAR), Ocular Therapeutix (OCUL), and Oscar Health (OSCR) – highlighting potential risks and opportunities for investors. The core message emphasizes the importance of understanding volatility and managing risk, particularly for those unprepared for significant fluctuations.

The article identifies Marriott as a “stock to sell,” primarily due to underperforming revenue per room, poor expense management leading to a low operating margin, and anticipated decreases in free cash flow. Despite its global scale and brand portfolio, Marriott’s financial situation warrants caution, as indicated by a valuation ratio of 31.3x forward P/E.

Ocular Therapeutix (OCUL) is presented as another “stock to sell” due to declining revenue, increasing expenses relative to revenue, and a significant contraction in free cash flow margins. The company’s reliance on a novel drug delivery platform is questioned, and the high valuation of 28x forward price-to-sales suggests overoptimism.

Conversely, Oscar Health (OSCR) is identified as a “stock to buy.” The article highlights robust annual revenue growth (41.2% over two years), increased adjusted operating profits due to cost efficiency, and an expanding free cash flow margin. Its technology-focused approach to the complex US healthcare system, combined with its cloud-native platform, is viewed positively. The valuation of 34.3x forward P/E is considered reasonable given its growth trajectory.

Beyond these individual stock analyses, the piece notes a broader market trend: a concentration of gains within just four stocks comprising half of the S&P 500's growth. This prompts a call for investors to seek out “quality where no one’s looking,” emphasizing the importance of identifying undervalued companies.

StockStory then promotes its own research service, highlighting a curated list of “High Quality” stocks that have achieved a market-beating return of 244% over the last five years (as of June 30, 2025). Examples include Nvidia and Comfort Systems, showcasing the potential for uncovering hidden gems.

Ultimately, the article urges investors to be discerning, acknowledge the inherent risks of volatile stocks, and actively seek out opportunities based on thorough research and a long-term perspective.

German Translation (approx. 500 words)

Zusammenfassung (ca. 500 Wörter)

Dieser Artikel von StockStory analysiert drei Aktien – Marriott (MAR), Ocular Therapeutix (OCUL) und Oscar Health (OSCR) – und beleuchtet potenzielle Risiken und Chancen für Investoren. Die Kernbotschaft betont die Bedeutung des Verständnisses von Volatilität und des Risikomanagements, insbesondere für unerfahrene Anleger.

Der Artikel identifiziert Marriott als eine “Aktie zum Verkaufen”, hauptsächlich aufgrund unterdurchschnittlicher Einnahmen pro Zimmer, schlechter Kostenkontrolle, die zu einer niedrigen operativem Gewinnmarge führt, und erwarteter Rückgänge im Free Cash Flow. Trotz seiner globalen Reichweite und seines Markenportfolios erfordert die finanzielle Situation von Marriott Vorsicht, wie durch ein Bewertung Verhältnis von 31,3x Forward P/E angezeigt wird.

Ocular Therapeutix (OCUL) wird als eine weitere “Aktie zum Verkaufen” dargestellt, da das Umsatzwachstum zurückgeht, die Kosten im Verhältnis zum Umsatz steigen und die Free Cash Flow Margen erheblich schrumpfen. Der Einsatz einer innovativen Medikamentenabgabepattform wird in Frage gestellt, und die hohe Bewertung von 28x Forward Price-to-Sales deutet auf Überoptimismus hin.

Im Gegensatz dazu wird Oscar Health (OSCR) als eine “Aktie zum Kaufen” identifiziert. Der Artikel hebt robustes Umsatzwachstum (41,2% über zwei Jahre), erhöhte angepasste operative Gewinnmarge aufgrund von Kosteneffizienz und eine wachsende Free Cash Flow Margen hervor. Sein technologieorientierter Ansatz für das komplexe US-Gesundheitssystem, kombiniert mit seiner cloud-basierten Plattform, wird positiv bewertet. Die Bewertung von 34,3x Forward P/E wird angesichts seiner Wachstumsdynamik als angemessen erachtet.

Über die Analysen der einzelnen Aktien hinaus weist der Artikel auf eine breitere Markttendenz hin: eine Konzentration der Gewinne innerhalb von nur vier Aktien, die die Hälfte des Gesamtwachstums des S&P 500 ausmachen. Dies führt zu einem Aufruf für Investoren, nach “Qualität zu suchen, wo niemand danach sucht”, und betont die Bedeutung der Identifizierung unterbewerteter Unternehmen.

StockStory bewirbt dann seinen eigenen Forschungsdienst, der eine kuratierte Liste von “Hochwertigen” Aktien hervorhebt, die in den letzten fünf Jahren eine marktübertretende Rendite von 244 % erzielt haben (zum 30. Juni 2025). Beispiele hierfür sind Nvidia und Comfort Systems, die das Potenzial für die Entdeckung verborgener Schätze zeigen.

Letztendlich fordert der Artikel Investoren auf, differenziert zu sein, die inhärenten Risiken volatiler Aktien anzuerkennen und aktiv Chancen auf der Grundlage einer gründlichen Recherche und einer langfristigen Perspektive zu suchen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Zusammenfassung

Der Gesundheitsversicherungssektor erlebte 2025 einen erheblichen Einbruch aufgrund unerwartet hoher Gesundheitskosten aus verschiedenen Quellen. Dies führte zu starken Kursverlusten für viele Versicherer, darunter die stark gebeutelte Oscar Health und UnitedHealth Group. Dennoch stellen dieser Einbruch Kaufchancen dar, da Analysten einen Erholungsturbo für diese Unternehmen, insbesondere im Jahr 2026, erwarten.

Oscar Health: Oscar Health, ein disruptiver Versicherer, der sich auf den Affordable Care Act (ACA) Markt konzentriert, hat aufgrund von Bedenken hinsichtlich auslaufender Subventionen für Geringverdiener des ACA, seinen Aktienkurs dramatisch fallen sehen. Zusätzlich zu den Problemen innerhalb von Oscar, die die Erwartungen übertrafen, führten sie zu gemeldeten Verlusten. Trotz dieser Widrigkeiten erwartet Oscar ein substanzielles Umsatzwachstum – potenziell bis 19 Milliarden Dollar – und erhebliche operative Gewinne (250 Millionen bis 450 Millionen Dollar) im Jahr 2026, getragen von Preiserhöhungen und verbesserter Kundenbindung. Mit einer Marktkapitalisierung von nur 3,6 Milliarden Dollar erscheint der Aktienkurs derzeit günstig bewertet.

UnitedHealth Group: Das riesige Krankenversicherungsunternehmen, UnitedHealth Group, hatte ebenfalls in 2025 zahlreiche Herausforderungen, darunter die von Oscar, sowie Cybersecurity-Probleme, Vorwürfe bezüglich überhöhter Gesundheitsleistungen für Medicare-Patienten und eine Kartellklage. Trotz dieser Schwierigkeiten erwartet UnitedHealth einen profitablen Wende in 2026, mit prognostizierten 439 Milliarden Dollar Umsatz und 24 Milliarden Dollar operativer Gewinne, dank von Premium-Tarifänderungen und demografischen Trends wie der Alterung der Bevölkerung. Derzeit wird der Aktienkurs mit einer Marktkapitalisierung von 260 Milliarden Dollar als relativ kostengünstige Investition (ungefähr 10x Gewinn) angesehen, unter Berücksichtigung des Wachstumspotenzials des Unternehmens.

Investitionsperspektive: Der Artikel legt nahe, dass sowohl Oscar Health als auch UnitedHealth Group attraktive Investitionsmöglichkeiten darstellen, insbesondere für Investoren, die auf der Suche nach Wachstum sind. Obwohl die kurzfristigen Risiken bestehen bleiben – insbesondere die ungewisse Auswirkung der ACA-Subventionen – wird das Potenzial für eine Erholung und zukünftigen Gewinnwachstum als signifikant angesehen.

Der Text betont die Bedeutung der Berücksichtigung größerer wirtschaftlicher Faktoren wie Gesundheitsinflation und demografischer Veränderungen bei der Bewertung dieser Aktien. Darüber hinaus hebt er den Erfolg des Motley Fool’s Stock Advisor Dienstes hervor, der das S&P 500 kontinuierlich übertroffen hat, und demonstriert so die potenziellen Vorteile von Investitionen auf der Grundlage von Empfehlungen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Zusammenfassung

Dieser Bericht von Yahoo Finance analysiert mehrere aufstrebende Aktien: Charles Schwab (SCHW), Stifel (SF), Paramount Skydance (PSKY) und Oscar Health (OSCR). Die Kernbotschaft dreht sich um die disruptive Wirkung künstlicher Intelligenz (KI) auf den Finanzsektor und den anhaltenden Versuch von Paramount Skydance, Warner Brothers Discovery zu übernehmen.

Die Analyse beginnt mit Vermögensverwaltungsunternehmen, insbesondere Schwab, Raymond James und Stifel, die aufgrund von Altrus’ KI-gestütztem Steuerplanungs-Tool “Hazel” unter Druck geraten. Dies hat eine Welle der Investorenschüchternheit ausgelöst, trotz insgesamt positiver Stimmung. Der Markt beurteilt das Potenzial von KI, traditionelle Finanzdienstleistungen überflüssig zu machen. Obwohl eine leichte Korrektur stattfand, bleibt die allgemeine Perspektive für Schwab vorsichtig optimistisch, wobei die Mehrheit der Analysten weiterhin Kaufempfehlungen gibt.

Als Nächstes ändert sich die Diskussion zu Paramount Skydances fortgesetztem Versuch, Warner Brothers Discovery zu übernehmen. Paramount hat eine 2,8 Milliarden Dollar fragefreie Kündigungsgebühr an Netflix erfüllt, was ihr Engagement für den Deal demonstriert. Warner Brothers hält sich weiterhin an sein bestehendes Fusionstemmen mit Netflix, trotz potenzieller Kartellermittlungen der DOJ im Zusammenhang mit der vorgeschlagenen Streaming-Dominanz von Netflix. Paramount erhöht sein Angebot auf über 100 Milliarden Dollar, zusätzlich zur Zahlung von 25 Cent pro Aktie für jedes Quartal, in dem der Deal bis zum 31. Dezember 2026 nicht abgeschlossen wird.

Schließlich steigen die Aktien von Oscar Health aufgrund einer verbesserten Prognose für die Rentabilität im Jahr 2026. Obwohl die Firma breitere Verluste aufgrund hoher Kunden-Nutzungsraten meldet, hat sie die Umsatz- und Gewinnprognosen übertroffen. Ein wichtiger Faktor für diese Optimismus ist eine prognostizierte durchschnittliche gewichtete Zinserhöhung von 28 % für 2026 sowie Anpassungen, die Veränderungen in der Mitgliederdemografie und der Deckungskategorie widerspiegeln. Dies verdeutlicht den anhaltenden Einfluss von Gesundheitsgesetzgebung, insbesondere Obamacare, auf die Leistung des Unternehmens.

Im Wesentlichen reagiert der Markt auf die strategischen Maßnahmen dieser Unternehmen inmitten einer breiteren Trend technologischer Störung und regulatorischer Kontrolle. Der Bericht unterstreicht die dynamische und wettbewerbsorientierte Landschaft innerhalb der Finanz- und Medienbranche.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Zusammenfassung (600 Wörter)

Am Dienstag erlebten die Aktienmärkte einen positiven Trend, der hauptsächlich auf einen Rekordkurs des Dow Jones Industrial Average (^DJI) zurückzuführen ist. Trotz eines enttäuschenden Berichts über den Einzelhandelsumsatz, der auf eine mögliche Verlangsamung der Konsumausgaben hindeutete, erholte sich das Anvertrauen der Investoren, insbesondere im Technologiebereich.

Der Dow stieg um rund 0,4 %, wobei auch der S&P 500 (^GSPC) und der Nasdaq Composite (^IXIC) um rund 0,1 % zunahmen. Dies folgte auf eine Phase der Schwäche, die durch Bedenken hinsichtlich Software und Megakonzernen im Technologiesektor verursacht wurde. Ein wichtiger Faktor für die Marktentwicklung war positive Nachrichten über den Umsatz von Halbleitern, insbesondere das Wachstum bei Nvidia (NVDA) und TSMC (TSM), das eine starke Nachfrage nach künstlicher Intelligenz (KI) anzeigt.

Der Kern der Marktbewegung lag im Veröffentlichung der Dezember-Einzelhandelsumsatzzahlen. Die Zahlen zeigten praktisch keinen Umsatzanstieg im Vergleich zu November, was im Vergleich zum Umsatzwachstum des Vormonats um 0,6 % ein deutlicher Rückgang war. Dieser Stopp deutete auf eine Verlangsamung der Konsumausgaben, insbesondere während der Weihnachtszeit, hin, und enttäuschte die Erwartungen der Analysten. Diese Daten schufen eine erhöhte Erwartung für den kommenden Mittwoch, den sehr erwarteten Bericht über die Januar-Beschäftigung, ein entscheidender Indikator für die Gesundheit der US-Wirtschaft, und den Bericht über den Verbraucherpreisindex (VPI) am Freitag, der Einblicke in die Inflationsdrucke geben würde.

Über die makroökonomischen Daten hinaus prüften Investoren aktiv die Quartalsergebnisse. Coca-Cola (KO) und CVS Health (CVS) veröffentlichten diese, aber Ford (F) war ein bemerkenswerter Höhepunkt nach dem Marktende.

Währenddessen setzte sich die volatile Performance von Kryptowährungen weiterhin im Blick der Investoren. Bitcoin (BTC-USD) erlebte einen Rückgang unter $69.000 nach einer Periode des Anstiegs über $5.000, die auf eine „Krise des Vertrauens“ zurückzuführen ist. Auch Gold (GC=F) verzeichnete einen leichten Rückgang, blieb aber dank anhaltend bullischer Stimmung bei den Banken, die potenzielle Erhöhungen bis Ende des Jahres auf $6.000 prognostizieren, über $5.000.

Darüber hinaus diskutieren Investoren weiterhin die Pläne der US-Regierung, Ausnahmen von bevorstehenden Chip-Zöllen für große Technologieunternehmen wie Amazon, Google und Microsoft zu gewähren, die an Investitionen von Taiwan Semiconductor Manufacturing Company (TSMC) geknüpft sind. Diese Maßnahme zielte darauf ab, den Aufstieg der KI-Sektor in den USA zu unterstützen, der stark auf importierte Halbleiter angewiesen ist. Dies spiegelt die Strategie von Präsident Trump wider, die Förderung der heimischen Chipproduktion zu fördern und die Bedürfnisse der Technologiebranche auszugleichen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Zusammenfassung (ca. 350 Wörter)

Mehrere große Unternehmen werden vor dem Eröffnung der Börse am Dienstag ihre Gewinnzahlen bekannt geben. Zu den wichtigsten Veröffentlichungsterminen gehören die von The Coca-Cola Company (KO), CVS Health Corporation (CVS), BP p.l.c. (BP), Duke Energy Corporation (DUK) und Datadog (DDOG). Diese Unternehmen repräsentieren eine vielfältige Auswahl von Sektoren, darunter Konsumgüter, Gesundheitswesen, Energie, Versorgungsunternehmen und Technologie.

Über diese Schlagzeilen hinaus bereiten sich auch eine große Anzahl anderer Unternehmen darauf vor, ihre Finanzberichte zu veröffentlichen. Diese umfangreiche Liste umfasst Unternehmen aus verschiedenen Branchen wie Luft- und Raumfahrt und Verteidigung (ACRE, AMTM, ARMK), Automobil (CAN), Chemie (CCSI), Verteidigung und Luftfahrt (ECL), Finanzdienstleistungen (FISV), Gaming (JMIA), industrielle Materialien (SLAB, XYL) und Technologie (AZN, DGX, ENTG, HAS, HMC, HOG, INCY, INMD, IRMD, SQNS, SPOT, WCC, WMB, XIFR).

Die enorme Anzahl der Gewinnberichte deutet auf eine arbeitsreiche Woche für Investoren hin, die diese Berichte sorgfältig prüfen werden, um Einblicke in die Unternehmensleistung und die zukünftige Perspektive zu gewinnen. Diese Informationen sind entscheidend für fundierte Anlageentscheidungen.

Seeking Alpha bietet einen umfassenden Gewinnkalender ([https://seekingalpha.com/earnings/earnings-calendar]), der Investoren hilft, die Veröffentlichungen zu verfolgen und die Daten zu analysieren. Der Kalender bietet einen detaillierten Zeitplan dafür, welche Unternehmen wann berichten, was eine wertvolle Ressource für Marktteilnehmer ist. Investoren können diesen Kalender nutzen, um Gewinnberichte zu antizipieren und ihre Handelsstrategien effektiv zu verwalten.